Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea [hydroxycarbamide] Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma.

Next Previous
X
Search
Trial Profile

Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea [hydroxycarbamide] Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydroxycarbamide (Primary) ; Imatinib (Primary)
  • Indications Glioblastoma
  • Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms AMBROSIA

    • Most Recent Events

    • 15 Apr 2011 Results of an analysis (n=101) that examined the prognostic and predictive value of platelet-derived growth factor alpha protein expression published in the International Journal of Cancer.
    • 01 Sep 2008 Results presented at the European Society for Medical Oncology.
    • 01 Sep 2008 Primary endpoint 'progression-free survival rate' has not been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top